Theravance, GlaxoSmithKline: Breo Ellipta approved for COPD treatment in Canada

GlaxoSmithKline (GSK) and Theravance (THRX) announced that BREO ELLIPTA has been approved in Canada for the long-term once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema, and to reduce exacerbations of COPD in patients with a history of exacerbations.

Advertisement